Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

STIFEL Europe Issues Buy Rating on Oxford Biomedica with Price Target of AUD 12.98

Oxford Biomedica PLC (LSE:OXB), a global cell and gene therapy contract development and manufacturing organisation (CDMO), has been assigned a“Buy” ratingfrom STIFEL Europe analyst James Orsborne, with aprice target of AUD 12.98 (equivalent to GBp 559.57). The rating reflects anupside of 12.41%against the current …

Sonal Goyal | 27 August 2025

Genedrive (AIM:GDR) Reports FY25 Trading Update and FY26 Outlook

Genedrive plc (AIM:GDR),a UK-based point-of-care pharmacogenetic testing company, has issued its unaudited trading update for the financial year ended 30 June 2025 (FY25), reporting an anticipated doubling of total income to approximately GBP 1 million compared to GBP 0.5 million in FY24 and GBP …

Team Kalkine | 11 August 2025

GSK (LON:GSK) Secures GBP 370m in CureVac-BioNTech mRNA Patent Settlement

GSK plc (LON:GSK),a global biopharmaceutical company headquartered in the UK, has announced financial terms related to a recently disclosed mRNA patent settlement between CureVac and BioNTech. As part of this agreement, GSK will receive a total of GBP 370 million upfront, along with ongoing …

Team Kalkine | 08 August 2025

Futura Medical (AIM:FUM) Appoints Interim CEO Amid Strategic Business Review

Futura Medical plc (AIM:FUM)has confirmed the appointment of Alex Duggan to its Board of Directors as interim Chief Executive Officer, following completion of all necessary due diligence and regulatory procedures. The appointment was initially announced on 8 July 2025 as part of a broader …

Team Kalkine | 08 August 2025

Berenberg Reaffirms Buy Rating on Hikma Pharmaceuticals with AUD 52.75 Price Target

Hikma Pharmaceuticals PLC (LSE: HIK.L), the multinational pharmaceutical group headquartered in the United Kingdom, has received a fresh endorsement from equity research houseBerenberg. AnalystVictoria Lamberthas reaffirmed herBuyrecommendation on the stock, assigning a price target ofAUD 52.75— representing a significant46.29% potential upsidefrom the current trading …

Sonal Goyal | 08 August 2025

Smith+Nephew (LSE:SN) Reports Growth in H1 Profit and Maintains FY25 Guidance, Shares Jump

Smith+Nephew plc (LSE:SN, NYSE:SNN),a global medical technology company, has released results for the six months ended 28 June 2025, reporting increases in trading profit, cash generation, and earnings per share. Underlying revenue grew 5.0% in the first half, with reported revenue rising 4.7%, reflecting …

Team Kalkine | 05 August 2025

Kooth Secures Triple BUY Ratings with Analysts Forecasting Over 200% Share Price Upside

Kooth Plc (LSE:KOO), a pioneering provider of digital mental health solutions, has received a wave of optimism from the market asthree leading analysts – Stifel Europe, Canaccord Genuity, and Berenberg – reaffirmed BUY ratings

Sonal Goyal | 30 July 2025

AstraZeneca (LON:AZN) H1FY25 Revenue Up 11%, EPS Rises 17%, US Expansion Planned

AstraZeneca plc (LON:AZN)is a global biopharmaceutical company headquartered in Cambridge, UK. The company focuses on the discovery, development, and commercialisation of prescription medicines, with a portfolio spanning Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism and Respiratory & Immunology), and Rare Disease. Its operations span …

Team Kalkine | 29 July 2025

AstraZeneca Commits $50 Billion to U.S. Expansion, Boosting Pharma Jobs and Innovation

AstraZeneca (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, significantly expanding its manufacturing and research presence across the country. The announcement builds on America’s leadership in pharmaceutical innovation and aims to increase local production capabilities while accelerating the …

Sonal Goyal | 22 July 2025

Craneware Delivers Positive FY25 Results, Analysts Reaffirms ‘Buy’ Rating with 19% Upside

Craneware plc (LSE:CRW.L), a leading provider of software solutions that enhance financial performance for the US healthcare sector, has delivered a positive trading update for FY25. The company reported a 12% increase in adjusted EBITDA to over $65 million, supported by a 9% rise …

Sonal Goyal | 18 July 2025
Support

Hi! How can we help you today?

Loading…